Sign in

You're signed outSign in or to get full access.

NP

NRX Pharmaceuticals, Inc. (NRXP)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 remained pre-revenue; net loss was $5.5M, improving year over year from $6.5M, but diluted EPS of -$0.34 missed S&P Global consensus of -$0.265 by $0.075; revenue estimate was $0 and actual $0 *.
  • Company advanced regulatory milestones: FDA waived the $4.3M NRX‑100 NDA filing fee; management guided to completing the NRX‑100 NDA in Q2 2025 and maintaining anticipated 2025 PDUFA timelines for NRX‑100 and NRX‑101 .
  • HOPE Therapeutics financing progressed: signed a $7.8M debt facility term sheet plus a $2.5M strategic investment for $10.3M of clinic acquisition capital, non‑dilutive to NRXP shareholders; initial acquisitions target ~$15M forward pro‑forma revenue and a $100M network target by YE25 .
  • Cash increased to $5.5M at quarter end, aided by Q1 financings; operating loss declined YoY on lower R&D and G&A, although non‑cash fair‑value items and debt-related losses impacted other expenses .

What Went Well and What Went Wrong

  • What Went Well

    • Regulatory momentum: “NRx’s 2024 momentum has continued into 2025… advanced regulatory filings for NRX‑100 and NRX‑101” .
    • Non‑dilutive clinic acquisition capital: $7.8M debt + $2.5M strategic investment term sheets executed for HOPE clinic roll‑up .
    • Cost discipline: R&D fell to $0.8M and G&A to $2.9M, driving lower operating loss versus prior year .
    • CEO quote: “We’ve accelerated our path to revenue with all 3 of our lead programs having potential to generate revenue in the foreseeable future.” .

  • What Went Wrong

    • EPS miss: Diluted EPS -$0.34 vs consensus -$0.265 (2 estimates), reflecting fair‑value losses and financing costs; revenue remained $0* .
    • Going‑concern disclosure: management noted substantial doubt about ability to continue as a going concern absent additional financing, despite current plans and discussions .
    • Other expense headwinds: loss on issuance and consideration shares/warrants ($0.7M and $1.3M), convertible note redemptions ($1.6M), and change in fair value of notes ($0.9M), partially offset by warrant remeasurement gain ($2.9M) .

Financial Results

MetricQ3 2024Q4 2024Q1 2025
Revenue ($USD Millions)$0.00 $0.00 $0.00
Net Loss ($USD Millions)$(1.62) n/a$(5.51)
Diluted EPS ($USD)$(0.15) n/a$(0.34)
Loss from Operations ($USD Millions)$(3.02) $(2.40) $(3.85)
R&D Expense ($USD Millions)$0.61 $1.00 $0.80
G&A Expense ($USD Millions)$2.41 $2.60 $2.94
Cash & Cash Equivalents ($USD Millions)$1.65 $1.40 $5.55

Estimates vs Actual (Q1 2025):

MetricConsensusActual
Revenue ($USD Millions)$0.00*$0.00
Diluted EPS ($USD)$(0.265)*$(0.34)

Note: Values with * retrieved from S&P Global.

KPIs and Balance Sheet Highlights

KPIQ3 2024Q4 2024Q1 2025
Working Capital Deficit ($USD Millions)n/an/a$(25.5)
Convertible Notes (Short-term) ($USD Millions)$3.05 n/a$8.40
Warrant Liabilities ($USD Millions)$1.90 $5.64 $9.85
Weighted Avg Shares (Basic/Diluted)10.97M n/a16.41M

Segment breakdown: Single operating segment; company did not generate revenue in Q1 2025 or FY 2024 .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
NRX‑100 NDA timeline (completion; PDUFA)2025Anticipated PDUFA by YE25; Module 3 filed Complete NDA in Q2 2025; 2025 PDUFA; $4.3M fee waived Maintained timeline; clarified schedule/fee waiver
NRX‑101 NDA (Accelerated Approval)2025Planned filing; anticipated PDUFA by YE25 “Remains on track” with anticipated 2025 PDUFA Maintained
HOPE Therapeutics clinic roll‑up revenue target2025Plan 15–20 FL facilities; 20 clinics at ~$5M each to meet target Initial 3 clinics ~$15M forward pro‑forma; aiming for $100M forward pro‑forma by YE25 Raised aggregate target and specificity
HOPE financingNear termNegotiating strategic TMS term sheet; bank financing $7.8M debt term sheet + $2.5M strategic investment; total $10.3M Progressed/secured term sheets
Cash runway2025Sufficient to fund operations through end of 2025 Management expects runway through at least end of 2025 Maintained

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4 2024)Previous Mentions (Q3 2024)Current Period (Q1 2025)Trend
Regulatory/legal (FDA path; citizen petition)NDA filing initiated for NRX‑100; plan ANDA; petition to remove benzethonium chloride Pre‑revenue; planning filings and financing FDA fee waiver; NDA completion Q2; 2025 PDUFA targets reaffirmed Positive momentum
FinancingTerm sheets; debt capital up to $16.3M; bank financing for HOPE SPA, offerings, convertible notes $7.8M debt + $2.5M investment term sheets for HOPE Progress to execution
HOPE clinic acquisitionsLOIs; Florida network plan; Kadima CMIO No revenue; building HOPE 3 initial acquisitions (Kadima, Dura, NeuroSpa); ~$15M pro‑forma; aim $100M Scaling plan
Manufacturing capacity>1M vials/month potential for ketamine n/aReiterated capacity and pH‑neutral HTX‑100 development Maintained; product pipeline expands
IP/patent strategyStability/sterility for preservative‑free ketamine; IP positioning n/aUS patent application; potential exclusivity through 2045 Strengthening IP
International expansionPotential EU filing via French data n/aManagement open to international NRX‑100 expansion interest Broadening

Management Commentary

  • “We’ve accelerated our path to revenue with all 3 of our lead programs having potential to generate revenue in the foreseeable future.” – CEO Jonathan Javitt .
  • “We’re making important progress building NRx into a company that will bring life-saving treatment to patients and financial returns to our investors.” .
  • “NRx’s 2024 momentum has continued into 2025… advancing regulatory filings for NRX‑100 and NRX‑101… and HOPE Therapeutics acquisitions.” .

Q&A Highlights

  • IP/exclusivity: Management believes preservative‑free ketamine IP could extend exclusivity beyond initially anticipated; pH‑neutral formulation expected to be patentable and long‑term protected .
  • ANDA/NDA approach: NDA adds psychiatric indications; ANDA aims to offer preservative‑free ketamine for existing indications, leveraging shared manufacturing data .
  • International expansion: Significant interest from international entities; Europe seen as receptive to preservative‑free NRX‑100 .
  • Acquisition cadence: Expect “chunky” acquisitions (multi‑clinic groups), with Florida as geographic focus and financing stack combining banks, equity, and seller consideration .

Estimates Context

  • EPS missed S&P Global consensus: -$0.34 actual vs -$0.265 estimate (2 estimates); revenue was in‑line at $0.00, reflecting pre‑revenue status (coverage is thin) *.
  • Implications: Non‑cash fair‑value losses and financing costs drove the variance; with HOPE clinic contributions targeted in 2025 and potential NDA approvals, forward revenue/EPS trajectories may necessitate estimate revisions as transaction closings and regulatory decisions firm up .

Note: Values with * retrieved from S&P Global.

Key Takeaways for Investors

  • Near‑term catalysts: Q2 NRX‑100 NDA completion, 2025 PDUFAs for NRX‑100/NRX‑101, and HOPE clinic acquisition closings; these events can re‑rate the stock narrative from pre‑revenue to visible commercialization .
  • Financing de‑risking: $10.3M of HOPE acquisition capital (debt + strategic investment) is non‑dilutive to NRXP shareholders and supports scaling the clinic network .
  • Operational discipline: Lower R&D/G&A reduced operating loss; watch fair‑value and financing‑related other expense items for quarter‑to‑quarter EPS volatility .
  • Balance sheet watch‑items: Working capital deficit and rising short‑term notes warrant close monitoring; management disclosed going‑concern risk absent additional financing .
  • IP moat: Preservative‑free ketamine patent filing and pH‑neutral formulation pipeline strengthen potential defensibility and differentiation .
  • HOPE revenue path: Initial acquisitions ~$15M forward pro‑forma, with $100M target by YE25; execution on closings and integration are key for EBITDA and cash generation .
  • Trading lens: Upcoming regulatory newsflow and acquisition closings are likely to be primary stock reaction drivers; thin consensus coverage can amplify moves on incremental disclosures .